Similarly, following this approach, a MUC1-based autologous dendritic cell (DC) vaccine given to prostate cancer patients was reported to be safe in phase I/II studies and elicited a significant CD4+/CD8+ T cell response [231]. This evidence concerns the gene CD8A and prostate carcinoma.